Klaus Kümmerer · Maximilian Hempel
Editors

Green and Sustainable Pharmacy

Springer
# Contents

## Part I  General Aspects

1. **Why Green and Sustainable Pharmacy?**  
   Klaus Kümmerer  
   3

2. **Pharmaceuticals in the Environment: Moving from a Problem to a Solution**  
   John P. Sumpter  
   11

3. **Pharmaceuticals in Society**  
   David J. Triggle  
   23

4. **Green(er) Pharmacy**  
   James H. Clark, Simon W. Breeden, and Louise Summerton  
   37

5. **Creating a Sustainability Culture – A (Human Resources) Management Perspective for Sustainable Pharmacy**  
   Michael Läufer  
   61

   Christian G. Daughton and Ilene S. Ruhoy  
   77

## Part II  Development, Synthesis and Production and Distribution of Pharmaceuticals

7. **Ecopharmacostewardship – A Pharmaceutical Industry Perspective**  
   David Taylor  
   105

8. **Protein and Peptide Therapeutics: An Example of “Benign by Nature” Active Pharmaceutical Ingredients**  
   Jürg Oliver Straub  
   127

9. **Rational Design of Molecules by Life Cycle Engineering**  
   Klaus Kümmerer  
   135
Part III  Use and Disposal of Pharmaceuticals

10 Options for a More Environmentally Friendly Handling of Pharmaceuticals .................................................. 149
Konrad Götz and Jutta Deffner

11 Disposal of Pharmaceutical Waste in Households – A European Survey ........................................... 165
Gerald Vollmer

12 Pharmaceutical Waste: The Patient Role .................................................. 179
Staffan Castensson and Anders Ekedahl

13 Forecast of Pharmaceutical Consumption in the Netherlands Using Demographic Projections ........... 201
Monique van der Aa and Geertjan Kommer

Part IV  Emission Management

14 Point Sources of Human Pharmaceuticals into the Aquatic Environment ............................................. 211
Kevin V. Thomas and Katherine H. Langford

15 Pharmaceuticals for Human Use: An Integrated Strategy for Reducing the Contamination of Water Bodies .......................................................... 225
Florian Keil

16 Experiences with the Swedish Environmental Classification Scheme ................................................. 243
Åke Wennmalm and Bo Gunnarsson

Part V  Incentives, Regulation and the Market

17 European Regulations .................................................. 253
Eleftheria Kampa, Thomas Dworak, Cornelius Laaser, and Rodrigo Vidaurre

18 Regulation and the Market-Incentives .................................................. 279
Benoît Roig and Evelyne Touraud

19 Do Pharmaceuticals in the Environment Present an Investment Risk? .................................................. 287
Andreas Holzer

Part VI  Outlook

20 Sustainable Health Products and Service Solutions in the Year 2050 .................................................. 295
Ludwig Metz and Klaus Kümmerer
21 Summary and Outlook ................................................. 299
Klaus Küмерer Maximilian Hempel,
Hans-Christian Schaefer, and Florian Keil

Index ............................................................................. 305